Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Identification of AV-1451 as a Weak, Nonselective Inhibitor of Monoamine Oxidase.

Drake LR, Pham JM, Desmond TJ, Mossine AV, Lee SJ, Kilbourn MR, Koeppe RA, Brooks AF, Scott PJH.

ACS Chem Neurosci. 2019 Aug 21;10(8):3839-3846. doi: 10.1021/acschemneuro.9b00326. Epub 2019 Aug 5.

PMID:
31339297
2.

Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.

van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, Reiman EM, Aisen PS, Strittmatter SM.

JAMA Neurol. 2019 Jul 22. doi: 10.1001/jamaneurol.2019.2050. [Epub ahead of print]

3.

Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.

Jassar H, Nascimento TD, Kaciroti N, DosSantos MF, Danciu T, Koeppe RA, Smith YR, Bigal ME, Porreca F, Casey KL, Zubieta JK, DaSilva AF.

Neuroimage Clin. 2019;23:101905. doi: 10.1016/j.nicl.2019.101905. Epub 2019 Jun 18.

4.

Cognitive Control as a 5-HT1A-Based Domain That Is Disrupted in Major Depressive Disorder.

Langenecker SA, Mickey BJ, Eichhammer P, Sen S, Elverman KH, Kennedy SE, Heitzeg MM, Ribeiro SM, Love TM, Hsu DT, Koeppe RA, Watson SJ, Akil H, Goldman D, Burmeister M, Zubieta JK.

Front Psychol. 2019 Mar 29;10:691. doi: 10.3389/fpsyg.2019.00691. eCollection 2019.

5.

Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies.

Su Y, Flores S, Wang G, Hornbeck RC, Speidel B, Joseph-Mathurin N, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Jack CR Jr, Farlow MR, Salloway S, Snider BJ, Berman SB, Roberson ED, Brosch J, Jimenez-Velazques I, van Dyck CH, Galasko D, Yuan SH, Jayadev S, Honig LS, Gauthier S, Hsiung GR, Masellis M, Brooks WS, Fulham M, Clarnette R, Masters CL, Wallon D, Hannequin D, Dubois B, Pariente J, Sanchez-Valle R, Mummery C, Ringman JM, Bottlaender M, Klein G, Milosavljevic-Ristic S, McDade E, Xiong C, Morris JC, Bateman RJ, Benzinger TLS.

Alzheimers Dement (Amst). 2019 Feb 22;11:180-190. doi: 10.1016/j.dadm.2018.12.008. eCollection 2019 Dec.

6.

Cholinergic system changes of falls and freezing of gait in Parkinson's disease.

Bohnen NI, Kanel P, Zhou Z, Koeppe RA, Frey KA, Dauer WT, Albin RL, Müller MLTM.

Ann Neurol. 2019 Apr;85(4):538-549. doi: 10.1002/ana.25430. Epub 2019 Mar 13.

7.

First-in-Human Studies of [18F] Fluorohydroxyphenethylguanidines.

Raffel DM, Jung YW, Koeppe RA, Jang KS, Gu G, Scott PJH, Murthy VL, Rothley J, Frey KA.

Circ Cardiovasc Imaging. 2018 Dec;11(12):e007965. doi: 10.1161/CIRCIMAGING.118.007965.

PMID:
30558502
8.

Utility of perfusion PET measures to assess neuronal injury in Alzheimer's disease.

Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, Gordon BA, Hornbeck RC, Cash L, Ances BM, Veale T, Cash DM, Brickman AM, Buckles V, Cairns NJ, Cruchaga C, Goate A, Jack CR Jr, Karch C, Klunk W, Koeppe RA, Marcus DS, Mayeux R, McDade E, Noble JM, Ringman J, Saykin AJ, Thompson PM, Xiong C, Morris JC, Bateman RJ, Benzinger TLS; Dominantly Inherited Alzheimer Network.

Alzheimers Dement (Amst). 2018 Sep 27;10:669-677. doi: 10.1016/j.dadm.2018.08.012. eCollection 2018.

9.

Futureproofing [18F]Fludeoxyglucose manufacture at an Academic Medical Center.

Sowa AR, Jackson IM, Desmond TJ, Alicea J, Mufarreh AJ, Pham JM, Stauff J, Winton WP, Fawaz MV, Henderson BD, Hockley BG, Rogers VE, Koeppe RA, Scott PJH.

EJNMMI Radiopharm Chem. 2018 Oct 5;3:12. doi: 10.1186/s41181-018-0048-x. eCollection 2018 Dec.

10.

Regional vesicular acetylcholine transporter distribution in human brain: A [18 F]fluoroethoxybenzovesamicol positron emission tomography study.

Albin RL, Bohnen NI, Muller MLTM, Dauer WT, Sarter M, Frey KA, Koeppe RA.

J Comp Neurol. 2018 Dec 1;526(17):2884-2897. doi: 10.1002/cne.24541. Epub 2018 Oct 19.

PMID:
30255936
11.

Classics in Neuroimaging: Radioligands for the Vesicular Monoamine Transporter 2.

Kilbourn MR, Koeppe RA.

ACS Chem Neurosci. 2019 Jan 16;10(1):25-29. doi: 10.1021/acschemneuro.8b00429. Epub 2018 Sep 10.

PMID:
30198706
12.

Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with [18F]-FEOBV.

Nejad-Davarani S, Koeppe RA, Albin RL, Frey KA, Müller MLTM, Bohnen NI.

Mol Psychiatry. 2019 Mar;24(3):322-327. doi: 10.1038/s41380-018-0130-5. Epub 2018 Aug 6. No abstract available.

13.

Deuterium Kinetic Isotope Effect Studies of a Potential in Vivo Metabolic Trapping Agent for Monoamine Oxidase B.

Drake LR, Brooks AF, Mufarreh AJ, Pham JM, Koeppe RA, Shao X, Scott PJH, Kilbourn MR.

ACS Chem Neurosci. 2018 Dec 19;9(12):3024-3027. doi: 10.1021/acschemneuro.8b00219. Epub 2018 Aug 17.

PMID:
30074755
14.

Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies.

Su Y, Flores S, Hornbeck RC, Speidel B, Vlassenko AG, Gordon BA, Koeppe RA, Klunk WE, Xiong C, Morris JC, Benzinger TLS.

Neuroimage Clin. 2018 Apr 25;19:406-416. doi: 10.1016/j.nicl.2018.04.022. eCollection 2018.

15.

Development of Positron Emission Tomography Radiotracers for the GABA Transporter 1.

Sowa AR, Brooks AF, Shao X, Henderson BD, Sherman P, Arteaga J, Stauff J, Lee AC, Koeppe RA, Scott PJH, Kilbourn MR.

ACS Chem Neurosci. 2018 Nov 21;9(11):2767-2773. doi: 10.1021/acschemneuro.8b00183. Epub 2018 May 24.

PMID:
29763549
16.

Preferential degradation of cognitive networks differentiates Alzheimer's disease from ageing.

Chhatwal JP, Schultz AP, Johnson KA, Hedden T, Jaimes S, Benzinger TLS, Jack C Jr, Ances BM, Ringman JM, Marcus DS, Ghetti B, Farlow MR, Danek A, Levin J, Yakushev I, Laske C, Koeppe RA, Galasko DR, Xiong C, Masters CL, Schofield PR, Kinnunen KM, Salloway S, Martins RN, McDade E, Cairns NJ, Buckles VD, Morris JC, Bateman R, Sperling RA; Dominantly Inherited Alzheimer Network.

Brain. 2018 May 1;141(5):1486-1500. doi: 10.1093/brain/awy053.

17.

A six-year longitudinal PET study of (+)-[11C]DTBZ binding to the VMAT2 in monkey brain.

Kilbourn MR, Koeppe RA.

Nucl Med Biol. 2017 Dec;55:34-37. doi: 10.1016/j.nucmedbio.2017.08.008. Epub 2017 Sep 5.

PMID:
29031997
18.

Normal Striatal Vesicular Acetylcholine Transporter Expression in Tourette Syndrome.

Albin RL, Minderovic C, Koeppe RA.

eNeuro. 2017 Aug 7;4(4). pii: ENEURO.0178-17.2017. doi: 10.1523/ENEURO.0178-17.2017. eCollection 2017 Jul-Aug.

19.

An updated synthesis of [11 C]carfentanil for positron emission tomography (PET) imaging of the μ-opioid receptor.

Blecha JE, Henderson BD, Hockley BG, VanBrocklin HF, Zubieta JK, DaSilva AF, Kilbourn MR, Koeppe RA, Scott PJH, Shao X.

J Labelled Comp Radiopharm. 2017 Jun 30;60(8):375-380. doi: 10.1002/jlcr.3513. Epub 2017 May 12.

PMID:
28419528
20.

Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo.

DaSilva AF, Nascimento TD, Jassar H, Heffernan J, Toback RL, Lucas S, DosSantos MF, Bellile EL, Boonstra PS, Taylor JMG, Casey KL, Koeppe RA, Smith YR, Zubieta JK.

Neurology. 2017 Apr 25;88(17):1634-1641. doi: 10.1212/WNL.0000000000003861. Epub 2017 Mar 29.

21.

[18F]Fluoro-Hydroxyphenethylguanidines: Efficient Synthesis and Comparison of Two Structural Isomers as Radiotracers of Cardiac Sympathetic Innervation.

Jung YW, Jang KS, Gu G, Koeppe RA, Sherman PS, Quesada CA, Raffel DM.

ACS Chem Neurosci. 2017 Jul 19;8(7):1530-1542. doi: 10.1021/acschemneuro.7b00051. Epub 2017 Mar 27.

22.

Correction: Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Sep 20;11(9):e0163669. doi: 10.1371/journal.pone.0163669. eCollection 2016.

23.

Intranasal Opioid Administration in Rhesus Monkeys: PET Imaging and Antinociception.

Saccone PA, Lindsey AM, Koeppe RA, Zelenock KA, Shao X, Sherman P, Quesada CA, Woods JH, Scott PJ.

J Pharmacol Exp Ther. 2016 Nov;359(2):366-373. Epub 2016 Sep 13.

24.

Investigation of Proposed Activity of Clarithromycin at GABAA Receptors Using [(11)C]Flumazenil PET.

Scott PJ, Shao X, Desmond TJ, Hockley BG, Sherman P, Quesada CA, Frey KA, Koeppe RA, Kilbourn MR, Bohnen NI.

ACS Med Chem Lett. 2016 Jun 1;7(8):746-50. doi: 10.1021/acsmedchemlett.5b00435. eCollection 2016 Aug 11.

25.

PET Amyloid Analyses.

Frey KA, Koeppe RA.

J Nucl Med. 2016 Aug;57(8):1168-9. doi: 10.2967/jnumed.116.173989. Epub 2016 Apr 14. No abstract available.

26.

Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Su Y, Blazey TM, Owen CJ, Christensen JJ, Friedrichsen K, Joseph-Mathurin N, Wang Q, Hornbeck RC, Ances BM, Snyder AZ, Cash LA, Koeppe RA, Klunk WE, Galasko D, Brickman AM, McDade E, Ringman JM, Thompson PM, Saykin AJ, Ghetti B, Sperling RA, Johnson KA, Salloway SP, Schofield PR, Masters CL, Villemagne VL, Fox NC, Förster S, Chen K, Reiman EM, Xiong C, Marcus DS, Weiner MW, Morris JC, Bateman RJ, Benzinger TL; Dominantly Inherited Alzheimer Network.

PLoS One. 2016 Mar 24;11(3):e0152082. doi: 10.1371/journal.pone.0152082. eCollection 2016. Erratum in: PLoS One. 2016 Sep 20;11(9):e0163669.

27.

Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation.

Haugen J, Müller ML, Kotagal V, Albin RL, Koeppe RA, Scott PJ, Frey KA, Bohnen NI.

J Neural Transm (Vienna). 2016 Apr;123(4):421-4. doi: 10.1007/s00702-016-1524-7. Epub 2016 Feb 24.

28.

Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease.

Petrou M, Davatzikos C, Hsieh M, Foerster BR, Albin RL, Kotagal V, Müller ML, Koeppe RA, Herman WH, Frey KA, Bohnen NI.

Acad Radiol. 2016 May;23(5):577-81. doi: 10.1016/j.acra.2015.07.014. Epub 2016 Feb 10.

29.

Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Shah N, Frey KA, Müller ML, Petrou M, Kotagal V, Koeppe RA, Scott PJ, Albin RL, Bohnen NI.

Mov Disord. 2016 Jan;31(1):111-7. doi: 10.1002/mds.26369. Epub 2015 Sep 18.

30.

Non-exercise physical activity attenuates motor symptoms in Parkinson disease independent from nigrostriatal degeneration.

Snider J, Müller ML, Kotagal V, Koeppe RA, Scott PJ, Frey KA, Albin RL, Bohnen NI.

Parkinsonism Relat Disord. 2015 Oct;21(10):1227-31. doi: 10.1016/j.parkreldis.2015.08.027. Epub 2015 Aug 28.

31.

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.

Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, Price JC, Foster NL, Wang AY.

Alzheimers Dement. 2015 Jul;11(7):757-71. doi: 10.1016/j.jalz.2015.05.001. Review.

32.

Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications.

Albin RL, Fisher-Hubbard A, Shanmugasundaram K, Koeppe RA, Burke JF, Camelo-Piragua S, Lieberman AP, Giordani B, Frey KA.

Ann Neurol. 2015 Nov;78(5):824-30. doi: 10.1002/ana.24481. Epub 2015 Aug 25.

33.

Educational attainment and motor burden in Parkinson's disease.

Kotagal V, Bohnen NI, Müller ML, Koeppe RA, Frey KA, Langa KM, Albin RL.

Mov Disord. 2015 Jul;30(8):1143-7. doi: 10.1002/mds.26272. Epub 2015 Jun 10.

34.

APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern.

Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR Jr, Beckett LA, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative (ADNI).

Alzheimers Dement. 2015 Dec;11(12):1417-1429. doi: 10.1016/j.jalz.2015.03.003. Epub 2015 May 7.

35.

Improved power for characterizing longitudinal amyloid-β PET changes and evaluating amyloid-modifying treatments with a cerebral white matter reference region.

Chen K, Roontiva A, Thiyyagura P, Lee W, Liu X, Ayutyanont N, Protas H, Luo JL, Bauer R, Reschke C, Bandy D, Koeppe RA, Fleisher AS, Caselli RJ, Landau S, Jagust WJ, Weiner MW, Reiman EM; Alzheimer’s Disease Neuroimaging Initiative.

J Nucl Med. 2015 Apr;56(4):560-6. doi: 10.2967/jnumed.114.149732. Epub 2015 Mar 5.

36.

It still hurts: altered endogenous opioid activity in the brain during social rejection and acceptance in major depressive disorder.

Hsu DT, Sanford BJ, Meyers KK, Love TM, Hazlett KE, Walker SJ, Mickey BJ, Koeppe RA, Langenecker SA, Zubieta JK.

Mol Psychiatry. 2015 Feb;20(2):193-200. doi: 10.1038/mp.2014.185. Epub 2015 Jan 20.

37.

Donald M. Wieland, Ph.D.

Raffel DM, Kilbourn MR, Koeppe RA.

Nucl Med Biol. 2015 Mar;42(3):213-4. doi: 10.1016/j.nucmedbio.2014.11.014. Epub 2014 Dec 9. No abstract available.

PMID:
25530209
38.

Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects.

Bohnen NI, Albin RL, Müller ML, Petrou M, Kotagal V, Koeppe RA, Scott PJ, Frey KA.

JAMA Neurol. 2015 Feb;72(2):194-200. doi: 10.1001/jamaneurol.2014.2757.

39.

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2015 Sep;11(9):1050-68. doi: 10.1016/j.jalz.2014.09.004. Epub 2014 Nov 24. Review.

40.

Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease.

Bohnen NI, Kotagal V, Müller ML, Koeppe RA, Scott PJ, Albin RL, Frey KA, Petrou M.

Parkinsonism Relat Disord. 2014 Dec;20(12):1394-8. doi: 10.1016/j.parkreldis.2014.10.008. Epub 2014 Oct 15.

41.

The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, Johnson KA, Mathis CA, Minhas D, Pontecorvo MJ, Rowe CC, Skovronsky DM, Mintun MA.

Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4. doi: 10.1016/j.jalz.2014.07.003. Epub 2014 Oct 28.

42.

Clinical markers for identifying cholinergic deficits in Parkinson's disease.

Müller ML, Bohnen NI, Kotagal V, Scott PJ, Koeppe RA, Frey KA, Albin RL.

Mov Disord. 2015 Feb;30(2):269-73. doi: 10.1002/mds.26061. Epub 2014 Nov 12.

43.

μ-Opioid activation in the midbrain during migraine allodynia - brief report II.

Nascimento TD, DosSantos MF, Lucas S, van Holsbeeck H, DeBoer M, Maslowski E, Love T, Martikainen IK, Koeppe RA, Smith YR, Zubieta JK, DaSilva AF.

Ann Clin Transl Neurol. 2014 Jun;1(6):445-50. doi: 10.1002/acn3.66. Epub 2014 Jun 1.

44.

Abnormal MoCA and normal range MMSE scores in Parkinson disease without dementia: cognitive and neurochemical correlates.

Chou KL, Lenhart A, Koeppe RA, Bohnen NI.

Parkinsonism Relat Disord. 2014 Oct;20(10):1076-80. doi: 10.1016/j.parkreldis.2014.07.008. Epub 2014 Jul 19.

45.

Association of μ-Opioid Activation in the Prefrontal Cortex with Spontaneous Migraine Attacks - Brief Report I.

DaSilva AF, Nascimento TD, DosSantos MF, Lucas S, van HolsbeecK H, DeBoer M, Maslowski E, Love T, Martikainen IK, Koeppe RA, Smith YR, Zubieta JK.

Ann Clin Transl Neurol. 2014 Jun 1;1(6):439-444.

46.

Functional connectivity in autosomal dominant and late-onset Alzheimer disease.

Thomas JB, Brier MR, Bateman RJ, Snyder AZ, Benzinger TL, Xiong C, Raichle M, Holtzman DM, Sperling RA, Mayeux R, Ghetti B, Ringman JM, Salloway S, McDade E, Rossor MN, Ourselin S, Schofield PR, Masters CL, Martins RN, Weiner MW, Thompson PM, Fox NC, Koeppe RA, Jack CR Jr, Mathis CA, Oliver A, Blazey TM, Moulder K, Buckles V, Hornbeck R, Chhatwal J, Schultz AP, Goate AM, Fagan AM, Cairns NJ, Marcus DS, Morris JC, Ances BM.

JAMA Neurol. 2014 Sep;71(9):1111-22. doi: 10.1001/jamaneurol.2014.1654.

47.

Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease.

Dodge HH, Zhu J, Harvey D, Saito N, Silbert LC, Kaye JA, Koeppe RA, Albin RL; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2014 Nov;10(6):690-703. doi: 10.1016/j.jalz.2014.04.513. Epub 2014 Jul 9.

48.

3D-neuronavigation in vivo through a patient's brain during a spontaneous migraine headache.

DaSilva AF, Nascimento TD, Love T, DosSantos MF, Martikainen IK, Cummiford CM, DeBoer M, Lucas SR, Bender MA, Koeppe RA, Hall T, Petty S, Maslowski E, Smith YR, Zubieta JK.

J Vis Exp. 2014 Jun 2;(88). doi: 10.3791/50682.

49.

Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.

Bohnen NI, Frey KA, Studenski S, Kotagal V, Koeppe RA, Constantine GM, Scott PJ, Albin RL, Müller ML.

Mov Disord. 2014 Aug;29(9):1118-24. doi: 10.1002/mds.25929. Epub 2014 Jun 7.

50.

Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease.

Kotagal V, Albin RL, Müller ML, Koeppe RA, Studenski S, Frey KA, Bohnen NI.

J Gerontol A Biol Sci Med Sci. 2014 Dec;69(12):1569-75. doi: 10.1093/gerona/glu070. Epub 2014 May 26.

Supplemental Content

Loading ...
Support Center